# CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

Source: https://onco.cc/trials/nct06690775/  
OnCo record `nct06690775` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of Pegfilgrastim in ovarian cancer, run by TORL Biotherapeutics, LLC, now recruiting.

## Summary

CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. is a phase 2 interventional study registered as NCT06690775 by TORL Biotherapeutics, LLC, with 230 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-10. Interventions recorded: TORL-1-23, TORL-1-23, TORL-1-23, Pegfilgrastim (drug). Conditions listed: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06690775
- Phase: 2
- Setting: Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
- Sponsor: TORL Biotherapeutics, LLC
- Enrolled: 230

## Sources

- ClinicalTrials.gov NCT06690775: https://clinicaltrials.gov/study/NCT06690775

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [Pegfilgrastim](https://onco.cc/drugs/pegfilgrastim/)

---
JSON: https://onco.cc/api/v1/entities/nct06690775.json